We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Potential Immune Markers Found for Active Tuberculosis

By LabMedica International staff writers
Posted on 18 May 2021
Print article
Image: Photomicrograph of Mycobacterium tuberculosis - Ziehl-Neelsen Acid-Fast Stains bacteria red (Photo courtesy of Rockefeller University)
Image: Photomicrograph of Mycobacterium tuberculosis - Ziehl-Neelsen Acid-Fast Stains bacteria red (Photo courtesy of Rockefeller University)
Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those affected.

Host immune responses at the site of M. tuberculosis infection can mediate pathogenesis of tuberculosis (TB) and onward transmission of infection. Immune responses at the site of M. tuberculosis infection can dictate pathogenesis within the infected individual and likelihood of transmission to others. The risk of active TB is also greater in persons suffering from other conditions that impair the immune system.

An international team of medical scientists led by the University College London (London, UK) hypothesized that pathological immune responses would be enriched at the site of host-pathogen interactions modeled by a standardized tuberculin skin test (TST) challenge in patients with active TB compared to those without disease, and interrogated immune responses by genome-wide transcriptional profiling. The team performed RNA sequencing on tuberculin skin test site biopsy samples from four dozen HIV-negative individuals diagnosed with pulmonary TB and from 191 HIV-negative individuals with latent TB, comparing expression profiles with those found following a control injection with saline.

The scientists reported exaggerated interleukin-17A (IL-17A) and T helper 17 (TH17) responses among 48 individuals with active TB compared to 191 with latent TB infection, associated with increased neutrophil recruitment and matrix metalloproteinase-1 expression, both involved in TB pathogenesis. Curative antimicrobial treatment reversed these observed changes. Increased IL-1β and IL-6 responses to mycobacterial stimulation were evident both in circulating monocytes and in molecular changes at the site of TST in individuals with active TB, supporting a model in which monocyte-derived IL-1β and IL-6 promote TH17 differentiation within tissues.

Gabriele Pollara, MBBS, PhD, a Medical Microbiologist and lead author of the study, said, “The distinctions that tip the balance between protective and pathogenic immune responses remain a fundamental question in tuberculosis studies. This knowledge is expected to inform rational vaccine design by identifying correlates of disease protection.”

The authors concluded that the availability of therapies that block IL-17A/F cytokine pathways, or upstream signals such as the IL-1-apha/beta and IL-6 axes, offers invaluable opportunities to transition from proof-of-concept pre-clinical studies to first-in-human experiments These studies are needed to establish the functional interaction between these cytokines and their causal role in the pathogenesis of human TB as a prelude to clinical trials for therapeutic benefit. The study was published on May 5, 2021 in the journal Science Translational Medicine.

Related Links:
University College London

New
Gold Supplier
Nucleic Acid Extractor
MGISP-NE384
New
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software
New
Influenza A/B Assay
Influenza A+B One Step Assay
New
Immunofluorescence Quantitative Analyzer
Quant-fluo 800

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.